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Abstract
Background Laparoscopic fenestration is one of the treatment options for symptomatic hepatic cysts, either solitary or in 
context of polycystic liver disease (PLD), but indications, efficacy and surgical techniques are under debate.
Methods A systematic literature search (1950–2017) of PubMed, Embase, Web of Science and the Cochrane Library was 
performed (CRD42017071305). Studies assessing symptomatic relief or symptomatic recurrence after laparoscopic fenes-
tration in patients with symptomatic, non-parasitic, hepatic cysts were included. Complications were scored according to 
Clavien–Dindo. Methodological quality was assessed by Newcastle–Ottawa scale (NOS) for cohort studies. Pooled estimates 
were calculated using a random effects model for meta-analysis.
Results Out of 5277 citations, 62 studies with a total of 1314 patients were included. Median NOS-score was 6 out of 9. 
Median follow-up duration was 30 months. Symptomatic relief after laparoscopic fenestration was 90.2% (95% CI 84.3–94.9). 
Symptomatic recurrence was 9.6% (95% CI 6.9–12.8) and reintervention rate was 7.1% (95% CI 5.0–9.4). Post-operative 
complications occurred in 10.8% (95% CI 8.1–13.9) and major complications in 3.3% (95% CI 2.1–4.7) of patients. Proce-
dure-related mortality was 1.0% (95% CI 0.5–1.6). In a subgroup analysis of PLD patients (n = 146), symptomatic recurrence 
and reintervention rates were significantly higher with respective rates of 33.7% (95% CI 18.7–50.4) and 26.4% (95% CI 
12.6–43.0). Complications were more frequent in PLD patients, with a rate of 29.3% (95% CI 16.0–44.5).
Conclusions Laparoscopic fenestration is an effective procedure for treatment of symptomatic hepatic cysts with a low symp-
tomatic recurrence rate. The symptomatic recurrence rate and risk of complications are significantly higher in PLD patients.
Keywords Hepatic cysts · Polycystic liver disease · Laparoscopic fenestration · Clinical outcomes
Simple hepatic cysts are fluid-filled cavities that arise from 
malformations of the ductal plate during embryonic devel-
opment. Simple hepatic cysts are a relatively common 
finding as it is estimated to be present in 2.5–18% of the 
general population [1, 2]. The presence of multiple cysts, 
arbitrarily > 10, is defined as polycystic liver disease (PLD) 
[3] and is usually part of the phenotype of two inherited 
disorders: autosomal dominant polycystic kidney disease 
(ADPKD) or autosomal dominant polycystic liver dis-
ease (ADPLD). Regardless of underlying pathology, these 
patients are at risk to develop large cysts, arbitrarily defined 
as > 5 cm in diameter. Large cysts may cause symptoms 
such as pain, loss of appetite, early satiety, nausea or dysp-
nea, sometimes causing a considerable decrease in quality of 
life [3, 4]. As such, treatment of large symptomatic cysts is 
indicated. Treatment options for large cysts comprise lapa-
roscopic fenestration, also termed laparoscopic deroofing 
or unroofing, and percutaneous aspiration sclerotherapy [5].
Laparoscopic fenestration combines cyst fluid aspira-
tion, followed by excision of extra-hepatic cyst wall in a 
single laparoscopic procedure. The surgical approach of 
large hepatic cysts has gained popularity since the 1990s, 
especially after the introduction of laparoscopy. As usual 
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in surgical practice, operative treatment has been gradually 
adopted in routine clinical care without valid comparison. 
Multiple cohort studies, however, suggest that laparoscopic 
fenestration is effective and safe in selected populations. 
Some surgeons routinely apply omentopexy (also termed 
omentoplasty, omental transposition or greater omentum 
flap), a procedure that applies omental tissue in the residual 
cyst cavity to prevent symptomatic recurrence. The merits 
and risks of omentopexy over and beyond mere laparoscopic 
fenestration are unexplored.
Percutaneous aspiration sclerotherapy is an alternative 
approach that percutaneously places a pigtail catheter in 
the cyst cavity to evacuate hepatic cyst fluid. After com-
plete drainage, a sclerosing agent (e.g. ethanol, tetracycline, 
polidocanol) is injected in the cyst which destroys the inner 
epithelial lining resulting in regression of the cyst. A recent 
clinical guideline suggests that symptomatic simple hepatic 
cysts may better be managed with laparoscopic fenestration 
rather than percutaneous aspiration sclerotherapy with the 
restriction of low quality of evidence [6]. It is imperative to 
quantify the benefits and risks of laparoscopic fenestration 
and to grade the evidence on this topic.
The purpose of this study was therefore to assess the effi-
cacy and safety of laparoscopic fenestration using a system-
atic review of the literature. The primary goal of treatment is 
alleviation of clinical symptoms, hence our focus on cohort 
studies and clinical trials that assessed symptomatic relief 
or symptomatic recurrence. We aim to give a comprehen-
sive summary of reported efficacy and safety rates of laparo-
scopic fenestration to aid in clinical decision-making when 
faced with symptomatic hepatic cysts.
Materials and methods
We conducted a systematic review of studies that evaluated 
the efficacy of laparoscopic fenestration for symptomatic 
simple hepatic cysts. This study was reported according to 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [7] and the Meta-anal-
ysis of Observational Studies in Epidemiology (MOOSE) 
checklist [8] (Supplementary File 1). The study protocol was 
registered in the Prospero database of systematic reviews 
(CRD42017071305) on 10 July 2017.
Eligibility criteria
We included cohort studies and clinical trials of adult 
patients with one or more simple (non-parasitic, non-neo-
plastic) and symptomatic hepatic cysts (excluding chole-
dochal cysts or hepatic foregut cysts), either solitary or 
in context of PLD, that underwent laparoscopic surgery 
with minimal resection of healthy liver parenchyma (e.g. 
fenestration, deroofing, unroofing). We included studies that 
assessed symptomatic relief and/or symptomatic recurrence. 
We excluded case reports, overlapping datasets, reviews, 
unpublished data and conference abstracts. We excluded 
studies with a mean or median follow-up < 6 months. For 
practical reasons, only articles in the following languages 
were included: Dutch, English, French, German, Italian and 
Spanish.
Literature search strategy
We systematically searched the electronic databases of Pub-
Med MEDLINE, Embase, Web of Science and the Cochrane 
Library from inception to 18 July 2017, without any restric-
tions. The search strategy combined terms related to hepatic 
cysts and laparoscopic interventions. The search terms were 
composed in collaboration with an experienced medical 
librarian. Exact search terms are presented in Supplemen-
tary File 2. If no full-text article was available, the original 
authors were emailed in order to gain access. References of 
included studies were checked for additional studies missed 
in the primary search. All identified records were exported 
to citation management program EndNote X8 (Clarivate 
Analytics, Philadelphia, PA, USA) for deduplication, which 
was performed according to a published protocol [9]. After 
deduplication, all records were exported to the browser-
based systematic review management program Covidence 
(Veritas Health Innovation, Melbourne, Australia. Avail-
able at http://www.covid ence.org). First, two investigators 
(LB and SE) independently screened title and abstract to 
determine the eligibility of each study. Second, the full-text 
of all included abstracts was independently assessed by the 
same investigators. Disagreements in both screening phases 
were resolved through discussion between the two investiga-
tors. Any remaining disagreement between reviewers was 
resolved through discussion with a third reviewer (CR, JD).
Data extraction
All data were extracted using standardised forms by one 
investigator (LB). Cases of uncertainty about data extrac-
tion were resolved through discussion between two inves-
tigators. Original data of four studies were requested by 
email. One author was able to send the additional data 
required for inclusion [10]. Data extraction was checked 
for errors by random sampling of 10% of included studies 
by a second investigator (SE), which did not show any 
errors. Our primary outcomes were symptomatic relief 
(i.e. full or partial symptomatic relief) directly after sur-
gery and symptomatic recurrence (recurrent symptoms 
with refilling or recurrent symptoms without confirma-
tion of refilling on imaging) during long-term follow-up. 
Secondary outcomes were study characteristics, patient 
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characteristics, reintervention rates, operative time, hospi-
tal stay, conversion to laparotomy and surgical technique. 
Reported rates of procedure-related complications and 
mortality were extracted. Reported post-operative com-
plications were scored according to the Clavien–Dindo 
classification [11] by one investigator (LB). Grade I and 
II were regarded as minor complications and grade III, IV 
and V as major complications.
Risk of bias assessment
We used the Newcastle–Ottawa scale for cohort stud-
ies to assess the risk of bias within individual studies. 
Adaptations were made a priori to make the scale more 
specific for our research question (Supplementary File 3). 
Using this scale, studies were scored on selection of study 
groups, the inclusion of a control group, the comparability 
of groups and the ascertainment of outcome of interest. 
Studies were independently scored by two investigators 
(LB, SE). Disagreements were resolved through discussion 
between two investigators.
Data synthesis and analysis
For meta-analysis of reported rates, pooled estimates and 
95% confidence intervals (CI) were calculated using a ran-
dom effects model for meta-analysis of prevalence, using 
MetaXL 5.2 (EpiGear, Sunrise Beach, Australia. Available 
at http://www.epige ar.com). When comparing means, not 
overlapping 95% CI were considered significant. When com-
paring medians, p value was calculated with Mann–Whitney 
test in GraphPad Prism 5 (GraphPad Software, La Jolla, CA, 
USA), p < 0.05 was considered significant.
Heterogeneity for pooled estimates was assessed using 
the I2 statistic, which describes the percentage of total vari-
ation across studies that is due to heterogeneity rather than 
chance. As we included a large number of studies, Cochran’s 
Q and p values are less practical for assessing heterogeneity 
[12]. Low, moderate and high heterogeneity was defined as 
an I2 value above 25%, 50% or 75%, respectively [12]. All 
I2 values were calculated with MetaXL.
Publication bias was assessed by generating funnel plots, 
where the standard error is plotted against the double arc-
sine transformed prevalence estimates of individual studies. 
Likelihood of publication bias was quantified using the Luis 
Furuya-Kanamori asymmetry index (LFK-index). An LFK-
index within 1 or − 1 indicates no asymmetry. An LFK-index 
exceeding 1 or − 1 but within 2 or − 2 indicates minor asym-
metry. An LFK-index exceeding 2 or − 2 indicates major 
asymmetry [13]. LFK-indices and funnel plots were gener-
ated with MetaXL.
Subgroup analyses
Potential causes of heterogeneity, as such influences on 
pooled estimates, were investigated by performing pre-
specified subgroup analyses of underlying disease, different 
surgical techniques, study design, publication date and fol-
low-up duration. Subgroups of non-categorical parameters 
were made by splitting included studies into two groups: 1: 
equal or below the median and 2: above the median.
All figures were made with Microsoft PowerPoint 2007 
(Microsoft Corporation, Redmond, WA, USA) and Graph-
Pad Prism 5.
Results
Systematic search
The systematic search identified 5278 citations. Ulti-
mately, 62 studies were included for this systematic review 
(Fig. 1A). Citations are presented in the supplementary files.
Study characteristics
The 62 included studies comprising a total of 1314 patients 
(Table 1). Studies from 5 different continents were included 
and most included studies were performed in Europe 
(Fig. 1B). The median number of patients per study was 
17 (total range 3–66). Of all included studies, 5 were pro-
spective cohort studies, 10 were retrospective analyses of 
prospectively collected data, 28 were retrospective cohort 
studies and 19 studies did not give an explicit statement on 
data collection. Publication dates ranged from 1994 to 2017. 
Study periods ranged between 1982 and 2015 (Fig. 2G). 
Median follow-up duration was 30 months (IQR 19–48) 
(Fig. 2A).
Of all included patients, 74% was female and 33% had 
PLD. Median age at time of operation was 58.7 years (IQR 
54.5–62.0) (Fig. 2B). Average preoperative cyst diameter 
was 11.9 cm (95% CI 11.1–12.7) (Fig. 2C). In 10 studies 
that did not exclusively operate on solitary cysts, median 
number of treated cysts was 1.4 (IQR 1.3–2.0; total range 
1.2–37.7). Individual study results are presented in Supple-
mentary File 4A–B.
Efficacy
There were 27 studies that reported the proportion of 
patients with full or partial symptomatic relief after surgery. 
Symptomatic relief was based on clinical follow-up data in 
25 studies, on a structured telephone interview in one study 
[14] and on a specific questionnaire in another study [15]. 
Pooled symptomatic relief was 90.2% (95% CI 84.3–94.9). 
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Symptomatic recurrence during follow-up was 9.6% (95% CI 
6.9–12.8). The rate of reintervention for the same cyst was 
7.1% (95% CI 5.0–9.4) (Table 2). Mean time until sympto-
matic recurrence was 16.1 months in 10 patients. Mean time 
until reintervention was 22.1 months in 13 patients.
Safety
Conversion from laparoscopic to open surgery during the 
procedure was necessary in 4.5% (95% CI 3.2–6.0), typically 
because of intra-operative bleeding, difficult positioning or 
extensive adhesions. Median hospital stay was 5.0 days 
(IQR 3.7–6.0) (Fig. 2D). Post-operative complication rate 
was 10.8% (95% CI 8.1–13.9), generally consisting of 
either bile leakage, ascites, pleural effusion or infections. 
Out of 136 reported post-operative complications, 115 
could be scored according to the Clavien–Dindo classifica-
tion (Fig. 2F). Of scored complications, 71.3% were minor 
and 28.7% were major. Overall, the pooled estimate of hav-
ing a major complication after surgery was 3.3% (95% CI 
Fig. 1  A PRISMA diagram. 
Flow chart representing lit-
erature search and elements of 
systematic review (identification 
and screening). B Illustrative 
schematic of country of origin 
of included studies. The number 
of inclusions per continent is 
shown
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2.1–4.7). The pooled estimate of procedure-related mortality 
was 1.0% (95% CI 0.5–1.6) (Table 2). This was based on a 
single patient from a series of 9 patients [16]. The patient 
presented with severe PLD symptoms. After an uneventful 
in-hospital stay, acute renal insufficiency ensued 20 days 
after discharge, followed by hepatorenal failure. The patient 
succumbed 15 days later. Other studies showed no proce-
dure-related mortality.
Operative technique
Median operative time was 83.5  min (IQR 72–120) 
(Fig. 2E). The use of omentopexy was explicitly mentioned 
in 31 studies that included a total of 824 patients. The 
pooled estimate for use of omentopexy was 14.8% (95% CI 
5.8–26.6), with a total range from 0 to 100% between stud-
ies. The use of concomitant cholecystectomy was mentioned 
in 37 studies that included a total of 822 patients. In 21.5% 
(95% CI 15.8–27.8) of patients, concomitant cholecystec-
tomy was performed; cited reasons were gallstones on image 
studies or cyst location adjacent to the gallbladder.
Risk of bias
An evaluation of the quality of individual studies is pre-
sented in Table 3, which provides details of risk of bias 
within studies, as reflected by adjusted Newcastle–Ottawa 
Scale (NOS) scoring. Overall, median score for ‘selection of 
study groups’ was 3 out of 4; median score for ‘comparabil-
ity of groups’ was 0 out of 2 and median score for ‘ascertain-
ment of outcome of interest’ was 3 out of 3. Median of the 
total NOS-score was 6 out of 9.
Table 1  Summary of included studies
# First author Year Np
1 Ammori 2002 3
2 Andriani 2000 17
3 Ardito 2013 47
4 Bai 2007 44
5 Caetano 2006 12
6 Cappellani 2002 9
7 De Reuver 2017 35
8 Debs 2016 27
9 Descottes 2000 15
10 Diez 1998 10
11 Emmermann 1997 18
12 Fabiani 2005 26
13 Faulds 2010 5
14 Fiamingo 2003 15
15 Gall 2009 61
16 Gamblin 2008 46
17 Gigot 2001 19
18 Gocho 2013 6
19 Hansen 1997 19
20 Hansman 2001 6
21 Heintz 1995 3
22 Hsu 2005 5
23 Kabbej 1996 13
24 Kamphues 2011 43
25 Katkhouda 2000 25
26 Kisiel 2017 48
27 Koea 2008 24
28 Konstadoulakis 2005 9
29 Koperna 1997 10
30 Kornprat 2004 21
31 Kwon 2003 14
32 Lee 2014 29
33 Lolle Noerregaard 2014 29
34 Manterola 2016 41
35 Marks 1998 17
36 Martin 1998 20
37 Martinez-Perez 2016 12
38 Maruyama 2013 16
39 Mazoch 2011 15
40 Mazza 2009 66
41 Morino 1994 11
42 Neri 2006 15
43 Palanivelu 2006 27
44 Pante 2014 7
45 Petri 2002 34
46 Regev 2001 18
47 Robinson 2005 11
48 Roesch Dietlen 1999 7
49 Sasi Szabo 2006 25
50 Schachter 2001 14
Last name of first author, year of publication
Np number of included patients per study
Table 1  (continued)
# First author Year Np
51 Scheuerlein 2013 47
52 Sendt 2009 27
53 Tagaya 2003 5
54 Tan 2005 10
55 Tocchi 2002 8
56 Torices 2004 21
57 Torres 2009 13
58 Treckmann 2010 42
59 Van Keimpema 2008 12
60 Wahba 2011 23
61 Wu 2014 30
62 Zacherl 2000 7
Total 1994–2017 1314
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Heterogeneity
Pooled estimates of outcomes were assessed for heterogene-
ity and publication bias. The  I2 value for symptomatic relief 
was 72%, for symptomatic recurrence 68%, for reinterven-
tion 50%, for complications 62%, indicating moderate het-
erogeneity. The I2 value for intra-operative conversions and 
for mortality was 0%, indicating negligible heterogeneity.
Publication bias
LFK-index for reintervention was 0.91, for complications 
0.42 and for intra-operative conversions 0.19, indicat-
ing no asymmetry. LFK-index for symptomatic relief was 
− 1.09, for symptomatic recurrence 1.11, indicating minor 
asymmetry. LFK-index for mortality was 2.87, indicating 
major asymmetry. Funnel plots are shown in Fig. 3.
Subgroup analyses
Polycystic liver disease
We performed a subgroup analysis of 15 studies that 
included only PLD patients or reported outcomes of PLD 
patients separately and compared these to the overall 
results (Table 2). Symptomatic recurrence and reinter-
vention rates were significantly higher with respective 
rates of 33.7% (95% CI 18.7–50.4) and 26.4% (95% CI 
12.6–43.0). Post-operative complications were more fre-
quent in PLD patients with a pooled estimate of 29.3% 
A B C
E F G
D
Fig. 2  A–E Analysis of continuous data: reported medians and 
means, Ns, number of studies. For reported means, the vertical line 
represents the median of means. C Preoperative cyst size, diameter in 
centimetres. F Scoring of post-operative complications according to 
Clavien–Dindo. G Timeframes wherein patients were included (study 
periods) are shown per study, sorted chronologically on first inclusion
Table 2  Overall versus PLD 
outcomes
Asterisk (*): statistically significant difference
PLD polycystic liver disease, Ns number of studies, Np number of patients, PE pooled estimate, CI confi-
dence interval
Outcome Ns Overall PLD
Np PE (%) 95% CI I2 (%) Ns Np PE (%) 95% CI I2 (%)
Recurrence 62 1314 9.6 6.9–12.8 68 15 146 33.7* 18.7–50.4 76
Reintervention 56 1176 7.1 5.0–9.4 50 10 109 26.4* 12.6–43.0 69
Complications 60 1276 10.8 8.1–13.9 62 13 129 29.3* 16.0–44.5 69
 Major 56 1106 3.3 2.2–4.7 27 13 129 7.2 2.1–14.6 46
Conversions 44 889 4.5 3.2–6.0 0 9 83 8.2 3.2–15.0 0
Mortality 60 1271 1.0 0.5–1.6 0 13 135 2.3 0.4–5.6 0
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(95% CI 16.0–44.5) (Fig. 4A). Out of 37 reported post-
operative complications, all could be scored according 
to Clavien–Dindo. Of scored complications, 70.3% were 
minor and 29.7% were major. Overall, the pooled estimate 
of having a major complication after surgery was 7.2% 
(95% CI 2.1–14.6). Conversion rate and procedure-related 
mortality did not differ significantly from overall results. 
Data were insufficient to analyse symptomatic relief in the 
PLD subgroup.
Omentopexy
For analysis of the effect of omentopexy on symptomatic 
recurrence rates, 31 studies that specified the use of omen-
topexy were split into two groups. As the median of addi-
tional omentopexy was 0%, studies were split accordingly. 
Group 1: no omentopexy performed. Group 2: omentopexy 
performed in 1 or more patients (total range 11–100%). For 
group 1, pooled symptomatic recurrence was 8.7% (95% 
Table 3  Risk of bias assessment 
(NOS)
Color coding: 0 1 2 3 4
Author
S. C. O. Score
Author
S. C. O. Score
0–4 0–2 0–3 0–9 0–4 0–2 0–3 0–9
Ammori 3 0 3 6 Lee 3 0 3 6
Andriani 3 0 2 5 Lolle Noerregaard 3 0 2 5
Ardito 2 0 3 5 Manterola 2 0 3 5
Bai 3 0 2 5 Marks 3 0 1 4
Caetano 3 0 2 5 Marn 3 0 3 6
Cappellani 3 0 3 6 Marnez-Perez 3 0 3 6
De Reuver 3 2 3 8 Maruyama 2 0 3 5
Debs 3 0 2 5 Mazoch 3 0 2 5
Descoes 2 0 3 5 Mazza 3 0 3 6
Diez 3 0 2 5 Morino 3 0 2 5
Emmermann 3 0 3 6 Ner 3 0 3 6
Fabiani 3 0 2 5 Palanivelu 3 0 3 6
Faulds 3 0 2 5 Pante 2 0 3 5
Fiamingo 3 0 3 6 Petri 2 0 2 4
Gall 3 0 1 4 Regev 2 0 3 5
Gamblin 3 0 3 6 Robinson 3 0 3 6
Gigot 3 0 3 6 Roesch Dietle 3 0 3 6
Gocho 3 0 3 6 Sasi Szabo 3 0 3 6
Hansen 3 0 3 6 Schachter 3 0 2 5
Hansman 2 0 2 4 Scheuerlein 3 0 3 6
Heintz 3 0 2 5 Sendt 3 0 3 6
Hsu 3 0 2 5 Tagaya 3 0 3 6
Kabbej 3 0 3 6 Tan 3 0 3 6
Kamphues 3 0 2 5 Tocchi 3 0 3 6
Katkhouda 3 0 3 6 Torices 3 0 3 6
Kisiel 3 0 1 4 Torres 3 0 3 6
Koea 3 0 3 6 Treckmann 3 0 2 5
Konstadoulakis 3 0 3 6 Van Keimpema 3 0 2 5
Koperna 3 0 3 6 Wahba 3 0 2 5
Kornprat 3 0 3 6 Wu 2 0 3 5
Kwon 3 0 3 6 Zacherl 3 0 3 6
Median 3 0 3 6
NOS Newcastle–Ottawa Scale, S selection of the study groups, C the comparability of the groups, O 
ascertainment of outcome of interest, Score total NOS-Score
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CI 3.4–16.0). For group 2, it was 5.7% (95% CI 3.0–9.3). 
In addition, we assessed the effect of omentopexy on post-
operative complication rates in the same groups. For group 
1, pooled complication rate was 8.4% (95% CI 5.2–12.2). 
For group 2, it was 11.0% (95% CI 5.8–17.5). In summary, 
there were no significant differences in pooled estimates 
of symptomatic recurrence rates and complication rates 
between groups. Data were insufficient to correct for cyst 
location and cyst size. (Fig. 4B–D).
Concomitant cholecystectomy
For analysis of the effect of concomitant cholecystectomy 
on symptomatic recurrence rates, 37 studies that specified 
the use of cholecystectomy were split into two groups. As 
the median proportion of patients that underwent additional 
cholecystectomy was 18.2%, studies were divided accord-
ingly. Group A: cholecystectomy in 18.2% of patients or 
less (total range 0–18.2%). Group B: cholecystectomy in 
Fig. 3  Funnel plots of meta-
analysis outcomes. The mod-
elled standard error is plotted 
against the double arcsine trans-
formed estimates of individual 
studies. Luis Furuya-Kanamori 
asymmetry index (LFK-index) 
is also shown
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more than 18.2% of patients (total range 21–80%). For 
group A, pooled symptomatic recurrence was 9.3% (95% 
CI 6.0–13.3). For group B, it was 7.3% (95% CI 3.0–13.3). 
Next, we focused on the effect of concomitant cholecys-
tectomy on post-operative complication rates in the same 
groups. For group A, pooled complication rate was 9.1% 
(95% CI 5.0–14.2). For group B, it was 7.6% (95% CI 
3.5–12.9). These data are consistent with the absence of 
significant differences in pooled estimates of symptomatic 
recurrence rates and complication rates between groups 
(Fig. 4F–H).
Follow-up duration
We were interested in the effect of prolonged follow-up on 
symptomatic recurrence rates. To this end, we selected 27 
studies that specified mean follow-up and distinguished 
into two groups. The median of reported mean follow-up 
duration was 30 months, and we categorised studies in two 
groups accordingly. Group I: mean follow-up duration of 
30 months or less (total range 6–30 months). Group II: mean 
follow-up duration of more than 30 months (total range 
36–86.4). For group I, pooled symptomatic recurrence was 
11.5% (95% CI 5.2–19.7). For group II, it was 6.8% (95% CI 
1.9–13.9). Thus, there was no significant effect of length of 
follow-up after six months on reported symptomatic recur-
rence rates (Fig. 4E).
Publication date
Publication dates ranged between 1994 and 2017, with the 
year 2005 as the median. Pooled symptomatic relief for 
studies published from 1994 to 2005 was 90.4% (95% CI 
84.0–95.4), and for studies published from 2006 to 2017 it 
was 92.2% (95% CI 82.0–98.7). Symptomatic recurrence 
for studies published from 1994 to 2005 was 9.8% (95% CI 
5.9–14.6) and for studies published from 2006 to 2017 it was 
9.1% (95% CI 4.4–13.5). Next, we assessed the effect of pub-
lication date on conversion rates. In studies published from 
1994 to 2005, the pooled conversion rate was 6.8% (95% 
CI 4.3–9.8) and for studies published from 2006 to 2017 it 
was 3.4% (95% CI 2.1–5.0). It must be noted that there were 
four studies with a conversion rate of 10% or higher and all 
were published before 2006 [16–19]. In studies published 
from 1994 to 2005, the pooled complication rate was 12.4% 
(95% CI 8.2–17.4) and for studies published from 2006 to 
A B C D E
F G H I J
K L M N O
Fig. 4  Subgroup analyses.  Ns: number of studies.  Np: number of 
patients. Interrupted lines: pooled estimates. Error bars: 95% confi-
dence intervals. A Outcomes for the polycystic liver disease (PLD) 
subgroup and overall results. B Percentage of patients that underwent 
omentopexy per included cohort. C, D Outcomes for omentopexy 
subgroups (Group 1: no omentopexy, Group 2: omentopexy). E Out-
comes for mean follow-up subgroups (Group I: ≤38 months, Group 
II: >38  months). F Percentage of patients that underwent concomi-
tant cholecystectomy per included cohort. G, H Outcomes for con-
comitant cholecystectomy subgroups (Group A: ≤ 21.5%, Group B: 
> 21.5%). I–L Outcomes for publication year subgroups (1994–2005 
and 2006–2017). M–O Outcomes for data collection subgroups (pro-
spective and retrospective)
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2017 it was 9.9% (95% CI 6.4–14.1). In studies published 
from 1994 to 2005, the median hospital stay was 5.3 days 
(IQR 4.0–6.3). In studies published from 2006 to 2017, the 
median hospital stay was 4.7 days (IQR 3.5–5.7), medians 
were not significantly different (p = 0.23). We can conclude 
that there were no significant effects of publication date on 
outcomes (Fig. 4I–L).
Data collection
To assess the effect of original study design on our primary 
outcomes, we performed a subgroup analysis on 15 studies 
that performed data collection prospectively and 27 studies 
that did retrospectively. In the prospective subgroup, sympto-
matic relief was 95.3% (95% CI 86.8–100.0%), symptomatic 
recurrence was 7.9% (95% CI 3.0–14.8) and complication 
rate was 6.9% (95% CI 3.0–12.2). In the retrospective sub-
group, symptomatic relief was 88.9% (95% CI 79.1–96.1), 
symptomatic recurrence was 12.5% (95% CI 8.3–17.4) and 
complication rate was 9.6% (95% CI 6.8–12.9). We can state 
that there were no significant effects of data collection on 
outcomes (Fig. 4M–O).
Discussion
Efficacy and safety
This systematic review describes the safety and efficacy of 
laparoscopic fenestration in 1314 patients reported in 62 
individual studies. We document that laparoscopic fenes-
tration of large, symptomatic cysts is effective and results in 
symptomatic relief in the large majority of patients. Symp-
tomatic recurrence after fenestration is low (9.6%) as is the 
reintervention rate for the same cyst (7.1%). Omentopexy 
after cyst fenestration did not improve efficacy, but also was 
not associated with a higher complication rate.
Laparoscopic fenestration appears to be a safe procedure 
and while procedure-related complications do occur in 11% 
of patients, scoring according to Clavien–Dindo shows that 
these are mostly minor and amenable to treatment. We were 
unable to assess the relation between pre-surgical cyst size, 
complication rate and recurrence rate. Concomitant chol-
ecystectomy is feasible, but does not contribute to the overall 
success of the procedure but similarly does not result in a 
higher complication rate.
The average interval between surgery and symptomatic 
recurrence was 16 months, and mean time until reinterven-
tion was 22 months. This interval should be interpreted very 
carefully because of the small sample size, but underscores 
the need for long-term follow-up when investigating cyst 
recurrence in future studies.
Patients with PLD may possess one or more large cysts 
against the background of multiple smaller cysts in sur-
rounding liver. Symptoms in PLD may be attributed to 
these large cysts and it may be tempting to perform lapa-
roscopic fenestration here. We found that this subgroup 
is at a high risk for complications and that long-term 
symptomatic relief is less well achieved. Potential causes 
of the elevated risk of complications are the changes in 
hepatic anatomy in PLD and the use of extensive fenes-
tration, with some studies fenestrating over 30 cysts per 
patient [16, 20]. The elevated recurrence rate is probably 
related to the different natural history of PLD and large 
solitary cysts. Hepatic cysts, regardless whether they are 
solitary or multiple, arise as a result from inactivation of 
2 alleles from PLD genes. PLD is a genetic disorder and 
patients have a germline mutation in one of the PLD genes 
and must acquire only one additional somatic mutation to 
develop cysts. Patients with solitary large cysts need to 
acquire somatic mutations on 2 PLD genes to develop the 
phenotype [3]. Thus, the risk for recurrence is low in these 
patients. This contrasts with the situation in PLD where 
the liver volume increases with 1.8% every 6–12 months. 
As a consequence, the natural growth of PLD will rapidly 
overtake the potential volume-curtailing effect of lapa-
roscopic fenestration of a single, albeit large, cyst. The 
implication is that the threshold for laparoscopic fenestra-
tion in PLD must be high in view of the limited long-term 
efficacy and higher risks.
Percutaneous aspiration sclerotherapy is a valid alter-
native strategy for large simple hepatic cysts. A recent 
systematic review found that aspiration sclerotherapy 
reduces symptoms in 72–100% while symptoms disap-
peared in 56–100% of patients. Aspiration sclerotherapy 
comes with complications such as pain, ethanol intoxica-
tion, cyst bleeding and rarely cyst infections [21]. It is 
essential to understand the dynamics of fluid reaccumula-
tion and disappearance after aspiration sclerotherapy to 
appreciate the merits of the procedure. Within days after 
complete evacuation of the cyst using aspiration sclero-
therapy, cyst fluid reaccumulates only to disappear slowly 
over (at least) 26 weeks [22]. As a corollary, aspiration 
sclerotherapy takes months to achieve its full effect, com-
pared to the immediate effect of fenestration. Despite these 
differences, it still needs to be determined which treatment 
is superior or which patient subgroup has the most benefit 
from either procedure. As percutaneous aspiration scle-
rotherapy and laparoscopic fenestration have never been 
compared directly in a controlled setting, we believe that 
a randomised trial that focuses primarily on symptomatic 
relief and symptomatic recurrence should be conducted. 
Subgroup analyses might elucidate patient-related factors 
that make either procedure better suited.
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Surgical technique
The question here is whether the evolution of laparoscopic 
fenestration is complete. In our dataset, we did not find a 
significant change in rates of efficacy, complications, con-
versions to laparotomy or length of hospital stay over time. 
Although conversion rates above 10% only occurred before 
2006. The basic surgical technique used is straightforward 
and entails laparoscopy, aspiration of cyst fluid first and 
finally wide deroofing of the cyst wall (near the transition 
zone between cyst wall and normal hepatic parenchyma). 
There are innovations such as the use of robot-assisted 
laparoscopic fenestration for giant hepatic cysts [23], sin-
gle incision laparoscopic surgery [24–30] or 3D-vision 
supported surgery [31]. In addition, the use of indocyanine 
green fluorescent imaging intra-operatively may facilitate 
better assessment of bile duct communication or identi-
fication of bile duct injuries [32–36]. However, the addi-
tive value of these techniques for cyst fenestration remains 
unclear.
Cyst recurrence is an issue and is thought to result from 
incomplete deroofing or development of a false lumen 
by adjacent tissues [37, 38]. To reduce recurrence risk, 
omentopexy is advocated in view of the hypothesis that 
omental tissue resorbs fluid and keeps the residual cavity 
open. Some authors cite specific indications to perform 
omentopexy such as a small exposed cyst wall, intrahe-
patic cysts, cyst size > 10 cm, cysts located posteriorly or 
in segment 7 and 8 or if < 50% of cyst wall can be resected 
[15, 39–45]. Other researchers refrain from omentopexy 
because of questionable evidence, similar recurrence rates 
without omentopexy, additional complications (e.g. omen-
tal bleeding) or extension of operating time [16, 46–49].
Our systematic review did not identify advantages or 
disadvantages of omentopexy as adjunct to the surgical 
procedure. One caveat is that the data were limited and no 
correction for cyst size and cyst location could be made. 
We included only studies that explicitly mentioned omen-
topexy in the subgroup analysis and it is possible that we 
missed data from studies that used the procedure but did 
not report that. Randomised clinical trial data are lacking 
but a single retrospective study compared fenestration with 
or without omentopexy and did not report a significant 
benefit [49]. In view of the limited benefit, the customary 
use of omentopexy with laparoscopic fenestration is ques-
tionable. Other options are in development to curtail cyst 
recurrence after deroofing such as ethanol sclerotherapy 
[50–53], argon beam coagulation [54, 55] or wide electro-
coagulation [56], but evidence to support their use is lim-
ited and the provided data were not sufficient to perform a 
subgroup analysis of these techniques.
Strengths and limitations of the study
There are a number of strengths and limitations that result 
from the very nature of a systematic review. The compliance 
with the recommendations of the PRISMA and MOOSE 
guidelines is a major strength of our systematic review. This 
included a pre-published protocol, an up-to-date extensive 
literature search, independent screening of all references 
by two authors and independent risk of bias assessment 
of included studies by two authors. Data extraction was 
checked for errors by random sampling of 6 studies by a sec-
ond investigator and was found 100% accurate. Contact with 
the corresponding authors of the included studies for addi-
tional information provided an extra inclusion. We excluded 
studies with a mean or median follow-up < 6 months to 
reduce biases in reported recurrence rates. Selection bias 
was reduced by excluding case series and all articles were 
methodically checked for presence of duplicate datasets. A 
limitation of our review is that we could not include some 
studies because of language restrictions and unavailable full-
text articles. This resulted in exclusion of some substantial 
Russian [57, 58], Ukrainian [59], Romanian [60], Hungar-
ian [61] and Chinese [62, 63] cohorts, which is a possible 
source of bias and may result in lower generalisability in 
other countries. In addition, an important question is if the 
location of the treated hepatic cyst correlates with a differ-
ent clinical response. It has been reported that unfavourably 
located cysts have a higher tendency for recurrence [17]. 
Unfortunately, the provided data were not sufficient to ana-
lyse this question in a subgroup analysis.
In our risk of bias assessment, studies scored well on 
selection of the study groups and ascertainment of outcome 
of interest. However, studies scored very low on compara-
bility of groups, as most studies did not include a control 
group. The implication is that the data collection resulted 
in a robust dataset but that comparison to untreated patients 
and correction for centre-dependent biases is not possible.
We observed moderate heterogeneity for the outcomes 
symptomatic relief, symptomatic recurrence, reinterven-
tion and complication rate. This is in part attributable to the 
diverse patient populations (PLD, solitary cysts or both). 
Our subgroup analyses established that omentopexy, chol-
ecystectomy, follow-up duration, publication date and data 
collection did not significantly affect the results and are an 
improbable cause of heterogeneity. Remaining causes of het-
erogeneity, that could not be assessed, are clinical diversity 
(e.g. centre, surgical expertise) and methodological diversity 
(e.g. study design, reporting).
Most outcomes had an LFK-index demonstrating minor 
or no asymmetry in the publication bias assessment, except 
for mortality. In theory, this could indicate that stud-
ies with high mortality were less likely to be published. 
However, as most studies had a prevalence of 0% and the 
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one reported procedure-related death occurred in a small 
cohort, the pooled mortality rate and LFK-index are prob-
ably overestimated.
No randomised controlled trials were included, and most 
included studies used patient records or prospective data-
bases. Only few studies used a validated questionnaire to 
assess symptoms and none used specific questionnaires such 
as the PLD-Q or POLCA [3]. In addition, not all studies 
had a clear definition of symptomatic recurrence and it is 
unclear if imaging had been performed for all patients during 
follow-up. In order to address this issue, we pooled patients 
with recurrent symptoms with evidence of radiological 
recurrence and patients with recurrent symptoms. By pool-
ing both categories it is possible that we included patients 
with recurrent symptoms without radiological recurrence. 
This could have affected our results. However, in included 
studies, only 3 out of 1203 patients had recurrent symptoms 
without radiological recurrence. We suggest that any future 
studies use validated questionnaires and standard imaging 
techniques at pre-set time points.
Conclusions
In conclusion, this systematic review provides evidence 
that laparoscopic fenestration is an effective treatment for 
symptomatic simple hepatic cysts with a low symptomatic 
recurrence rate. The symptomatic recurrence rate and risk 
of complications are significantly higher in PLD patients.
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